Pfizer Inc PFE

$29.80 +0.01 (0.03%)

Valuation

Market cap
171,161,200,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.97
Forward PE
10.33
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
12,519,877
Avg volume
32,104,324
Day's range
$29.51 – $29.86
Shares out
5,699,674,000
Stochastic %K
66%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Merlintrader Oct 27, 6:51 PM
Biotech recap for Oct 26–27: $ARTV, $BEAM, $MRK and $PFE lead more than 100 news items from these two days, covering trial readouts, FDA decisions, deals, offerings, earnings dates and upcoming conferences. https://www.merlintrader.com/biotech-radar-october-26-27-2026/ Not investment advice.
0 replies
SellasgpsCurativeBAT11 Oct 27, 6:11 PM
$ABBV $BMY $JNJ $PFE $SLS PPS will start moving Rapidly towards the base floor before the PR hits. Good Bye 👋🏿 Repositioners, Traders, Shorts 🔥 ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 27, 5:58 PM
$ABBV $BMY $JNJ $PFE $SLS Valuation Projections BO. 👇 ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 27, 5:40 PM
$ABBV $BMY $JNJ $PFE $SLS Top line will set the base floor at $120.00+ than BO $200.00+ Now all the dominos will in place very quickly. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 27, 5:26 PM
$ABBV $BMY $JNJ $PFE $SLS 🤩 👇 ✌️🙏❤️‍🩹
1 replies
SellasgpsCurativeBAT11 Oct 27, 5:22 PM
$ABBV $BMY $JNJ $PFE $SLS 500,000 share blocks going through ask now. Now that was a $6 million purchase at ASK. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 27, 4:55 PM
$ABBV $BMY $JNJ $PFE $SLS Part 2. I don’t Believe Sellas will be a stand alone Co. by AI Generated next ER date 11/11/26 which is 10 trading days from today. Sellas will be part of Final Big Pharmaceutical with the best offer. ✌️🙏❤️‍🩹
1 replies
SellasgpsCurativeBAT11 Oct 27, 4:46 PM
$SLS $JNJ $BMY $PFE $ABBV A major cash buyout will rapidly move the POS toward the agreed offer price. What makes the upside exciting is the possibility of GPS Ad Infinitum becoming standard maintenance therapy in AML's second remission, followed by expansion into earlier remission, post-transplant treatment and 20+ WT1-expressing cancers through sBLA’s With SLS009 also Progressing as a Blockbuster Platform, a buyer will acquire two complementary oncology assets with considerable expansion potential. Sellas is now in price discovery, the phase where the real-world market value or acceptable clearing price is tested and established before a final binding agreement is signed. BOD have 4 Business dats to PR final deal. ✌️🙏❤️‍🩹
1 replies